Form 4: Rapport Therapeutics CDO's Stock Vesting & Tax Sale

Rapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, reported the vesting of 9,000 performance-based restricted stock units and the subsequent sale of 2,840 shares to cover tax obligations.

Summary

• Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics, Inc. (RAPP), reported changes in beneficial ownership.
• On December 31, 2025, 9,000 shares of common stock were acquired due to the vesting of performance-based restricted stock units (PSUs).
• These PSUs were granted on December 4, 2024, and vested after the company's Compensation Committee confirmed the satisfaction of specified performance criteria as of December 31, 2025.
• Following this acquisition, the reporting person's direct beneficial ownership increased to 299,831 shares.
• Concurrently, on December 31, 2025, 2,840 shares of common stock were disposed of at a price of $30.05 per share.
• This disposition was a non-discretionary sale to cover tax withholding obligations related to the PSU vesting and settlement.
• After both transactions, the reporting person's direct beneficial ownership stands at 296,991 shares.

Sentiment

Score: 7

Explanation: The vesting of performance-based restricted stock units is a positive indicator of management achieving set goals. The subsequent sale for tax purposes is a routine, non-discretionary event and does not reflect a negative sentiment from the insider.

Positives

• The vesting of 9,000 performance-based restricted stock units indicates that specified performance criteria were met, reflecting positively on company and management performance.
• The Chief Development Officer's continued significant direct beneficial ownership of 296,991 shares aligns management's interests with shareholders.

Negatives

• The sale of 2,840 shares, even if for tax purposes, reduces the Chief Development Officer's direct equity stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The vesting of PSUs suggests management is meeting performance targets, which is generally positive for shareholder value. The tax-related sale is a minor, non-discretionary reduction in insider ownership.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation. The vesting of performance-based units is a positive signal regarding management's achievement of internal targets, but the subsequent sale is purely for tax purposes and not a discretionary move. Such a filing typically has minimal direct impact on the company's fundamental valuation or immediate share price, thus a "hold" recommendation is appropriate as it doesn't provide new information warranting a change in investment thesis.

Keywords

Rapport Therapeutics, RAPP, Form 4, SEC filing, insider transaction, stock vesting, PSU, restricted stock units, Chief Development Officer, Yeleswaram Krishnaswamy, equity ownership, tax withholding